Lara Longpre is CHIEF DEVELOPMENT OFFICER at Mirum Pharmaceuticals, Inc. (MIRM). They have made 6 open-market trades across 1 company since 2019, most recently 2024-02-02.
CIK 0001780347
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $10K since 2019, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| MIRM | 105,372 | $10.2M |
Shares reported on the most recent Form 4, priced at the 2024-03-18 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| MIRM | SELL | 2024-02-02 | 2024-02-05 | $26.19 | $22K | +10.5% | +8.4% | +0.6% |
| MIRM | SELL | 2024-01-08 | 2024-01-09 | $28.04 | $29K | -3.9% | -1.9% | -5.8% |
| MIRM | SELL | 2023-07-03 | 2023-07-05 | $25.65 | $26K | +5.4% | +2.8% | +15.7% |
| MIRM | SELL | 2023-01-09 | 2024-03-18 | $20.62 | $21K | -5.6% | -10.4% | +24.0% |
| MIRM | SELL | 2021-10-01 | 2021-10-01 | $19.26 | $19K | -12.1% | -15.6% | -18.3% |
| MIRM | BUY | 2019-09-10 | 2024-03-18 | $10.64 | $10K | -5.6% | -10.4% | +24.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.